36
Clinical Discussion Dr Pankaj Chaturvedi Professor and Surgeon Tata Memorial Hospital [email protected]

Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

  • Upload
    others

  • View
    8

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Clinical Discussion

Dr Pankaj ChaturvediProfessor and Surgeon

Tata Memorial Hospital

[email protected]

Page 2: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 47/M/smoker

• Hopkins : Trans-glottic lesion

• No cartilage infiltration but sclerosis

• Left vocal cord fixed

• No nodes palpable

Glottic Ca -T3 N0 MO

Page 3: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q1 - VOTING Options

1. Surgery -A. Open partial Laryngectomy

B. Laser cordectomy

2. Concurrent Cisplatin + RT

3. Neo adjuvant Chemotherapy

4. Cetuximab + RT

5. Radiotherapy Alone

Page 4: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Total Laryngectomy TEP PORT

T3 N0 MO Glottic Carcinoma

Page 5: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Author Year T3

5yr LC

T4

5yr LC

Mendenhall et al 1996 68% 56%

Daugaard et al 1998 38% 29%

Santos et al 1998 12% (OS) 14%(OS)

Sykes et al 2000 67% 73%

Hinerman et al 2002 62% 62%

Radiotherapy for Stage 3 / 4 larynx cancers

Is there a role of RT alone ?YES or NO

Page 6: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Does NACT still have a role?Yes / No

Page 7: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Is there a role of Cetuximab +RT

Bonner et al. N Eng J Med 2006;354:567-578

Page 8: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Surgeon

Page 9: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• Review of 158,426 cases of larynx cancer between 1985-2001

• Trend toward decreasing survival from the mid-1980s to mid-1990s

• Patterns of initial management across this same period: ↑CTRT and ↓Surgery

• Survival outcome of T3N0M0 laryngeal cancer in 1994-96 period: Poor 5Yr OS with CTRT (59.2%) and RT alone (42.7%) compared to Sx+RT (65.2%) or Sx alone (63.3%)

• The decreased survival recorded for patients with laryngeal cancer in the mid-1990s may be related to changes in patterns of management.

Page 10: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Despite improvement identified overall for all cancer types, survival among patients with laryngeal cancer has diminished. Data from SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute; 2003. Available at: http://seer.cancer.gov/csr/1975_2000 Published by Hoffman et al

Page 11: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 47/M/Chronic smoker

• Hoarseness

• Hopkins : Pyriform

• Cartilage not involved

• Left vocal cord fixed

• No nodes palpable

Page 12: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q2 - Voting Options

1. Surgery Followed by CT/RT

2. Concurrent Chemo Radiotherapy

3. Neo-adjuvant Chemotherapy

4. Targeted Therapy with RT

5. Radiotherapy alone

Page 13: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

45 yrs young man – Stage 4 a

Page 14: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q3 - Voting Options

1. Surgery Followed by CT/RT

2. Concurrent Chemo Radiotherapy

3. Neo-adjuvant Chemotherapy

Page 15: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Primary Chemotherapy in Resectable OSCC : A Randomized Controlled Trial. J Clin Oncol 2003;21:327-333. L Licitra et al

• Resectable, stage T2-T4(>3 cm), N0-N2 SCC of oral cavity

• PF followed by surgery vs surgery with or without radiotherapy

• No difference in overall survival

Role of Induction chemotherapy in resectableoral cancers?

Page 16: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Randomized Phase III Trial of ICT with Docetaxel, Cisplatin and FU Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable OSCC J ClinOncol. 2012 Nov 5; L Zhong et al

• Resectable stage III or IVA OSCC

• The control and experimental arms did not differ significantly in locoregional recurrence rates.

• Estimated 2-year OS and DFS was same

Role of Induction chemotherapy in resectableoral cancers

Page 17: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

NACT – Does it help?

Patil V M, Noronha V, Muddu V K, Gulia S, Bhosale B, Arya S, Juvekar S, Chatturvedi P, ChaukarD A, Pai P, D'cruz A, Prabhash K. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?. Indian J Cancer 2013;50:1-8

Induction chemotherapy was effective in converting technically unresectable oral cavity cancers to operable disease in approximately 40% of patients and was associated with significantly improved overall survival in comparison to nonsurgical treatment.

Page 18: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Stage 4B

• 52 year Truck Driver• Lesion involving right Buccal Mcosaand extensive infiltration• No distant metastases

Page 19: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q3 - Voting Options

1. Neo adjuvant Chemotherapy

2. Palliative Chemotherapy

3. Palliative Radiotherapy

4. Best Supportive Care

Page 20: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

•56 yrs male, underwent Surgery for Stage 4 Carcinoma Buccal Mucosa with PORT with Chemotherapy

•At first follow up at 4 months diagnosed with recurrence• PET Scan – local recurrence alone

Page 21: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q 4 - VOTING Options

1. Symptomatic Treatment

2. Palliative Chemotherapy

3. Targeted Therapy

4. Surgery if Resectable

Page 22: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• Recurrent/ Metastatic HNSCC

• Cetuximab + Platin + Flurouracil Vs Platin + Flurouracil

• About 20% oral cavity patients

• Better outcome in cetuximab arm

– 2.7 mo median OS improvement ( 10.1 mo Vs 7.4 mo)

– 2.3 mo median PFS improvement (5.6 mo Vs 3.3 mo)

Page 23: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• Palliative chemotherapy is the standard option for most patients with recurrent or metastatic HNSCC

– First line option should be combination of cetuximab with platin and flurouracil

Cetuximab has a definitive role as a firstl ine therapy along with platin and flurouracil for recurrent and metastatic oral cancer

Page 24: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• Result

– QALY increased: 0.093

– Cost increased: $36,000 per person

– Incremental cost effectiveness ratio of $386,000 per QALY gained.

Page 25: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Metronomic Therapy

• Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis. Indian J Cancer 2013;50:135-41

• Patil V, Noronha V, D'cruz A K, Banavali S D, Prabhash K. Metronomic chemotherapy in advanced oral cancers. J Can Res Ther 2012;8:106-10

Comparison of DFS between the oral metronomic scheduling of anticancer therapy and control groups

Page 26: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 3x3cm ulcer Rt. lateral border of tongue

• Not crossing midline / FOM - normal.

• T2N1M0

Page 27: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q5 - Voting Options

• Wide Excision alone

• Wide Excision with Neck Dissection

• Neo adjuvant CT

• Radiotherapy alone

Page 28: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Management issues

• Imaging• Surgery or Radiotherapy• Margins• Neck node management• Sentinel Node Biopsy?• Reconstruction • Should we do HPV testing?

Page 29: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 61/M

• Tobacco chewer

• Presented with Right sided neck mass 2.5 months.

• O/E- Right neck, Level II palpable node 5x4 cm.(N2a)

• PET CT – Nodal Mets only

Carcinoma of Unknown Origin

Page 30: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Q 6 - VOTING Options

1. Surgery followed by CT RT 2. Concurrent CT and RT

Other issues –1. HPV 2. Bilateral Mucosal Radiation3. Tonsillectomy

Page 31: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 38/F

• Left Parotid lesion operated 1 month back

• Details of surgery not available.

• Facial nerve intact

• HPR – Mucoepidermoidcarcinoma (intermediate grade) - 3 cm

• Margin status unknown

Page 32: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

MRI

Page 33: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Question

– Repeat Surgery

–Adjuvant RT

Page 34: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

• 45/F

• Presented with Left Thyroid swelling since 4 years

• FNAC – Bethesda 2

• USG – Benign lesion left lobe. Right lobe normal

• Left Hemi thyroidectomydone

• HPR – Well Diff Pap Ca, 3 cm no ETS, uni-focal

What next?

Page 35: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous

Question

• Observation alone

• Observation + Thyroid suppression

• Molecular Markers for decision making

• Completion thyroidectomy alone

• Completion thyroidectomy with bilateral CCND

• Lobar ablation with RAI

Page 36: Clinical Discussion · • Pai P S et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous